Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Adverum Biotechnologies revenue
Adverum Biotechnologies's revenue is $3.6 million.
What is Adverum Biotechnologies's revenue?
- Adverum Biotechnologies's revenue growth from 2013 to 2023 is 650.0%.
- Adverum Biotechnologies has 188 employees, and the revenue per employee ratio is $19,148.
- Adverum Biotechnologies's peak quarterly revenue was $7.5M in 2021(1).
- Adverum Biotechnologies peak revenue was $7.5M in 2021.
- Adverum Biotechnologies annual revenue for 2021 was 7.5M, 2,900.0% growth from 2019.
- Adverum Biotechnologies annual revenue for 2023 was 3.6M, -52.0% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Adverum Biotechnologies historical revenue
Adverum Biotechnologies's peak revenue was $7.5M in 2021. The peak quarterly revenue was $7.5M in 2021(1).
Adverum Biotechnologies's revenue increased from $480.0k in 2013 to $3.6M currently. That's a 650.0% change in annual revenue.
Adverum Biotechnologies annual revenue
Adverum Biotechnologies annual revenue over time
| Fiscal year / year | Adverum Biotechnologies revenue |
|---|---|
| 2013 | $480,000 |
| 2014 | $572,000 |
| 2015 | $2.3M |
| 2016 | $1.5M |
| 2017 | $1.8M |
| 2018 | $1.6M |
| 2019 | $250,000 |
| 2021 | $7.5M |
| 2023 | $3.6M |
Rate Adverum Biotechnologies' financial transparency
Adverum Biotechnologies annual growth
Adverum Biotechnologies saw the greatest revenue growth in 2021, when revenue increased by 2,900.0%.
Adverum Biotechnologies had the lowest revenue growth in 2019, when revenue changed by -84.49%.
Adverum Biotechnologies annual growth rate over time
| Year | Adverum Biotechnologies growth |
|---|---|
| 2014 | 19%↑ |
| 2015 | 305%↑ |
| 2016 | -37%↓ |
| 2017 | 27%↑ |
| 2018 | -13%↓ |
| 2019 | -84%↓ |
| 2021 | 2900%↑ |
| 2023 | -52%↓ |
Adverum Biotechnologies quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Adverum Biotechnologies quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | - | - | - | - |
| 2015 | - | - | - | - |
| 2016 | - | - | - | - |
| 2017 | - | - | - | - |
| 2018 | - | - | - | - |
| 2019 | - | - | - | - |
| 2021 | - | - | - | - |
| 2023 | - | - | - | - |
Adverum Biotechnologies jobs nearby
Do you work at Adverum Biotechnologies?
Did Adverum Biotechnologies meet its revenue projections?
Adverum Biotechnologies financial information
| CEO | Laurent Fischer |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 188 |
| Date Founded | 2006 |
| Headquarters | Menlo Park, California |
| Number of Locations | 2 |
| Revenue | $3.6M |
| Net Income | -$154,536,000 |
| Tax Rate | 0.0% |
| Total Assets | $308,372,000 |
| Ticker | ADVM |
Adverum Biotechnologies jobs you might like
Adverum Biotechnologies financing
Adverum Biotechnologies received early financing of $5.7M on 2013-11-26.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $5.7M | 11/2013 |
| Series B | $55M | 04/2014 |
| Post Ipo Equity | $10.0M | 09/2014 |
| Post Ipo Equity | $141.6M | 01/2015 |
| Post Ipo Equity | $69M | 02/2018 |
| Post Ipo Equity | $150.2M | 02/2020 |
| Post Ipo Equity | $217M | 08/2020 |
Adverum Biotechnologies investors
| Investors | Security type |
|---|---|
| Redmile Group | Series B |
| Venrock | Series B |
| Deerfield | Series B |
| Adage Capital Management | Series B |
| Sabby Capital | Series B |
| Rock Springs Capital | Series B |
Adverum Biotechnologies competitors
Adverum Biotechnologies's top competitor, Gilead Sciences, earned an annual revenue of $28.8B.
Adverum Biotechnologies's smallest competitor is GlobeImmune with revenue of $6.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | $85,008 | $2.0B | 900 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 598 |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 23 |
| Exelixis | $108,978 | $2.2B | 484 | 126 |
| Cubist Pharmaceuticals | $91,725 | $926.4M | 873 | - |
| Quidel | $71,489 | $1.7B | 1,500 | - |
| Iovance Biotherapeutics | $101,673 | $164.1M | 319 | 20 |
| GlobeImmune | $49,176 | $6.5M | 22 | - |
| Upsher-Smith Laboratories | $63,937 | $420.0M | 550 | 9 |
Adverum Biotechnologies revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Adverum Biotechnologies highest paying jobs
Zippia gives an in-depth look into the details of Adverum Biotechnologies, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Adverum Biotechnologies. The employee data is based on information from people who have self-reported their past or current employments at Adverum Biotechnologies. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Adverum Biotechnologies. The data presented on this page does not represent the view of Adverum Biotechnologies and its employees or that of Zippia.
Adverum Biotechnologies may also be known as or be related to ADVERUM BIOTECHNOLOGIES INC., Adverum Biotechnologies, Adverum Biotechnologies Inc and Adverum Biotechnologies, Inc.